ESSENTIAL THROMBOCYTHEMIA

This study is testing a combination of drugs to see if it can better prepare patients with advanced blood cancers for a stem cell transplant from a donor. The goal is to control the aggressive cancer cells before the transplant, which may help the new donor cells take hold and fi…

This study is testing a modified, gentler two-step method to prepare patients for a stem cell transplant. The goal is to reduce the risk of death from the transplant procedure itself for people with various blood cancers and disorders. Researchers are comparing two lower-intensit…

This study aims to see if a new drug called bomedemstat works better and is safer than the current standard treatment, hydroxyurea, for people with essential thrombocythemia (ET) who are starting treatment for the first time. It will involve 300 participants and will measure how …

This study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…

This study is testing a medication called peginterferon alfa-2b for adults with essential thrombocythemia, a blood disorder that causes high platelet counts and increases clotting risk. It's specifically for patients who cannot take or don't respond to the standard first-line tre…

This study is testing whether a new drug called bomedemstat works better than current standard treatments for people with essential thrombocythemia, a blood disorder where the body makes too many platelets. It's for patients who didn't respond well to or couldn't tolerate their p…

This is the first study in people to test a new drug called JNJ-88549968 for blood cancers with a specific genetic change (CALR mutation). The main goals are to find a safe dose and understand how the body handles the drug. The drug works by guiding a patient's own immune cells t…

This large Phase 3 trial aims to prevent life-threatening blood clots in people with certain high-risk blood cancers. It will compare newer, more potent blood thinners (apixaban/rivaroxaban) against standard low-dose aspirin in over 1,300 patients. The goal is to see if the newer…

This study is testing whether the drug ruxolitinib can reduce the often severe symptoms experienced by people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 participants with significant symptom burdens will take ruxolitinib for at least 6 months…

This study aims to find the best dose of N-Acetylcysteine (N-AC), a common supplement, to help reduce symptoms in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It will enroll 27 adults with ET, PV, or MF who have significant symptom burden. The main g…

This study is testing whether a curcumin supplement, the active ingredient in turmeric, can reduce inflammation and improve symptoms in people with certain blood cell disorders. Researchers will compare the supplement to a placebo in 30 participants over 12 months. The main goals…

This study aims to see if tracking the amount of a specific gene mutation (CALR) in a patient's blood over time can help doctors predict how their blood cell disorder will progress. It will follow 260 adults with these disorders for up to three years, collecting blood samples to …

This study aims to learn how a specific type of immune cell, called a monocyte, behaves in people with certain blood cancers. Researchers will collect blood samples from 70 participants who have not yet started treatment for their condition. By analyzing these cells, they hope to…